Survival of patients with malignant intestinal neoplasms according to right- or left-sided primary location
DOI:
https://doi.org/10.17696/2318-3691.26.3.2019.1661Keywords:
Digestive System Diseases; Intestinal Neoplasms; Colorectal Neoplasms; Oncology Nursing; Survival RateAbstract
Introduction. Colon neoplasms have a worldwide epidemiological relevance. Due to their molecular and clinical heterogeneity, early diagnoses and treatment are essential for survival gain. Survival and outcome prediction in colon neoplasms also are related to the primary location of the disease, especially the laterality of the neoplasms. Objective. To investigate the association between patients’ survival rates with right- or left-sided colon neoplasms.Methods. This is a cross-sectional study with descriptive design, analytical quantitative approach with correlation among variables. Study sample was composed of patients attended at a hospital complex in the São Paulo State inland from 2010 to 2017. Data were acquired from the Cancer Hospital Records and computerized medical records. We used IBM SPSS Statistical Package V.25 (IBM Corporation) to analyze the sociodemographic, clinical-pathological, and survival data, presenting them as median, interquartile ranges, and Kaplan Meier curve, according to the nature of the variables.Results. The sample was composed of 691 patients. Most of them (n=392;56.7%) had a diagnosis of left-sided colon neoplasm (56.7%), especially sigmoid neoplasm (n=282; 40.9%). We observed a slight predominance of men (n=351;50.8%), between stages II (n=193;27.9%) and III (n=213;30.9%). Tubular adenocarcinomas were the most frequent morphological type (n= 477; 69%). Age ranged from 14 to 97 (Median 63.7) years.Most of patients were self-declared as white (n=623;90.2%) and lived in the cities of XV Regional Health Department (n=408;59%).There were 296 (42.8%) deaths in the study period, especially patients with right-sided colon neoplasia (n=149; 50.3%).The overall survival had a median of 807 days (interquartile range [25th percentile = 284]; [interquartile range] 75th percentile = 1622).For patients with left-sided colon, the median was 866 days, and 675 days for patients with right-sided colon neoplasm.Conclusion. Right-sided colon neoplasms can be a possible independent predictor of death (survival of 1.8 years) when compared to left-sided colon neoplasms (survival of 2.4 years).
References
Murray CJL, Phil D, Lopez AD. Measuring the Global Burden of disease. N Engl J Med 2013; 369(5):448-57. DOI: 10.1056/NEJMra1201534
Ministério da Saúde. Instituto Nacional de Câncer - INCA [homepage na Internet]. [acesso em 2018 Jun 19]. Incidência de Câncer no Brasil: Estimativa 2018; [aproximadamente 1 tela]. Disponível em: http://www.inca.gov.br/estimativa/2018/index.asp
Reis JQ, Silva MRS, Costa GS. Prevenção do câncer colorretal em pacientes assintomáticos. Rev Uningá Review [periódico na Intermet] 2017 [acesso em 2019 Mar 18]; 29(3):118-22. Disponível em: http://revista.uninga.br/index.php/uningareviews/article/view/1985
American Cancer Society [homepage na Internet]. American Cancer Society; 2019 [acesso em 2019 Jun 19]. American Cancer Society Guideline for Colorectal Cancer Screening; [aproximadamente 4 telas]. Disponível em: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html
Ferreira JC, Patino CM. What is survival analysis, and when should I use it?. J Bras Pneumol. 2016;42(1):77. http://dx.doi.org/10.1590/S1806-37562016000000013
Bustamante-Teixeira MT, Faerstein E, Latorre MR. Técnicas de análise de sobrevida. Cad Saúde Pública . 2002;18(3):579-94. http://dx.doi.org/10.1590/S0102-311X2002000300003
Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17(2):79-92. doi: 10.1038/nrc.2016.126
Santo GFE, Aguilar-Nascimento JE, Kishima MO, Takiuchi A. Correlação de fatores anatomopatológicos com a sobrevida de pacientes operados por adenocarcinoma colorretal. Rev Col Bras Cir. 2008;35(3):182-7. http://dx.doi.org/10.1590/S0100-69912008000300009
Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713-29. doi: 10.1093/annonc/mdx175
Schrag D, Weng S, Brooks G, Meyerhardt JA, Venook AP, et al. The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol. 2016;34:15(Supl):3505. DOI: 10.1200/JCO.2016.34.15_suppl.3505
Venook AP, Kimmie NG. Left vs. Right: anatomic location matters for clinical outcomes in advanced colorectal cancer. In: ASCO Annual Meeting, Abstract 3504, 2016. Disponível em: https://am.asco.org/left-vs-right-anatomic-location-matters-clinical-outcomes-advanced-colorectal-cancer?utm_source=TrendMD&utm_medium=cpc&utm_campaign=ASCO_Daily_News_TrendMD_0 [acesso em 04 Junho 2019]
Venook AP. Tumor ‘Sidedness’ in Colon Cancer: studies look for explanations. In: ASCO Annual Meeting; 2017 [acesso em 2019 Jun 4]. Disponível em: http://www.ascopost.com/issues/july-25-2017/tumor-sidedness-in-colon-cancer-studies-look-for-explanations/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=The_ASCO_Post_TrendMD_0
Dalfovo MS, Lana DA, Silveira A. Métodos quantitativos e qualitativos: um resgate teórico. Rev Interdiscip Cient Apl [periódico na Internet], 2008 [acesso em 2019 Maio 7]; 2(4):1-13. Disponível em: rica.unibes.com.br/index.php/rica/article/download/243/234
Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Informação dos registros hospitalares de câncer como estratégia de transformação: perfil do Instituto Nacional de Câncer José Alencar Gomes da Silva em 25 anos. Rio de Janeiro: INCA; 2012.
Marotti M. Quais são os objetivos clínicos que determinam a eficácia dos tratamentos em oncologia? Rev Assoc Med Bras. 2007;53(6): 477-8. http://dx.doi.org/10.1590/S0104-42302007000600007
Ferreira JC, Patino CM. What is survival analysis, and when should I use it?. J Bras. Pneumol. [Internet], 2016; 42(1):77-77. http://dx.doi.org/10.1590/S1806-37562016000000013
Arnold M, Sierra MS, Laversanne M, SoerjomataramI, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-91. http://dx.doi.org/10.1136/gutjnl-2015-310912
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. [Internet], 2017;67(3):177-93. https://doi.org/10.3322/caac.21395
Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer, J Nat Cancer Inst. 2015;107(3):1-9. https://doi.org/10.1093/jnci/dju427
Carneiro Neto JD, Barreto JBP, Freitas NS, Queiroz MA. Câncer colorretal: características clínicas e anatomopatológicas em pacientes com idade inferior a 40 anos. Rev Bras Colo-Proctol. 2006;26(4):430-5. http://dx.doi.org/10.1590/S0101-98802006000400009
Price TJ, Beeke C, Ullah S, Padbury R, Maddern G, Roder D, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer. 2015;121(6):830-5. doi: 10.1002/cncr.29129
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105(1):58-64. doi: 10.1038/bjc.2011.201
Lupinacci RM, Campos FG, Araujo SEA, Imperiale AR, Seid VE, Habr-Gama A, et al. Análise comparativa das características clínicas, anátomo-patológicas e sobrevida entre pacientes com câncer colo-retal abaixo e acima de 40 anos de idade. Rev Bras Coloproct [periódico na Internet]. 2003 [acesso em 2019 Dez 19];23(3):155-62. Disponível em: file:///C:/Users/30062/Downloads/ANALISE_COMPARATIVA_DAS_CARACTERISTICAS_CLINICAS_A.pdf
Biondi A, Vacante M, Ambrosino I, Cristaldi E, Pietrapertosa G, Basile F. Role of surgery for colorectal cancer in the elderly. World J Gastrointest Surg. 2016; 8:606-13. doi: 10.4240/wjgs.v8.i9.606
Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2014;44(4):388-96. https://doi.org/10.1093/jjco/hyu003
Grosso G, Biondi A, F Galvano, Mistretta A, S Marventano, Buscemi S, et al. Factors associated with colorectal cancer in the context of the Mediterranean diet: a case-control study. Câncer Nutr. 2014;66(4):558-65. doi: 10.1080/01635581.2014.902975
Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15(9):1330-8. https://doi.org/10.1093/annonc/mdh344
Viana ALA, Silva HP, Ferreira MP. Demografia das regiões de saúde brasileiras [Internet]. São Paulo: RESBR; 2015. (Nota técnica, nº 6). Disponível em: http://www.resbr.net.br/wp-content/ uploads/2015/11/Novos-Caminhos-6.pdf [acesso em 03 Dezembro 2018]
Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: implications for age at initiation of screening. Br J Cancer. 2007;96(5):828-31. doi: 10.1038/sj.bjc.6603628
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Junior EL. Prognostic importance of comorbidity in a Hospital-based cancer registry. JAMA. 2004;291(2):2441-7. doi:10.1001/jama.291.20.2441
Bertolazzi LG, Domingues Junior JL, Carmo VCMFO, Fernandez FLC. Prevalência de diabetes em pacientes com neoplasias malignas de trato intestinal em um hospital de ensino. Rev Bras Oncol Clín [periódico na Internet]. 2015 [acesso em 2019 Jun 22];11(40):71-7. Disponível em: https://www.sboc.org.br/sboc-site/revista-sboc/pdfs/40/artigo3.pdf [acesso em 22 Junho 2019]
Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, Levine DA. Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol. 2017;147(3):621-5. https://doi.org/10.1016/j.ygyno.2017.09
Souza VB, Silva EN, Ribeiro ML, Martins WA. Hipertensão arterial no paciente com câncer. Arq Bras Cardiol. 2015;104(3):246-52. http://dx.doi.org/10.5935/abc.20150011
Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152-60. https://doi.org/10.1016/j.pharmthera.2017.08.012
Almeida RGL, Pontes ACAA, Cardoso DA, Carrera JS, Sousa MS, Maia CSF. O manejo da êmese em uma unidade oncológica: a necessidade da intervenção farmacêutica em tempo real. Rev Bras Cancerol [periódico na Internet]. 2015 [acesso em 2018 Dez 13];61(2):115-21. Disponível em: http://www1.inca.gov.br/rbc/n_61/v02/pdf/05-artigo-o-manejo-da-emese-em-uma-unidade-oncologica-a-necessidade-da-intervencao-farmaceutica-em-tempo-real.pdf
Van Zutphen M, Kampman E, Giovannucci EL, Van Duijnhoven FJB. Lifestyle after colorectal cancer diagnosis in relation to survival and recurrence: a review of the literature. Curr Colorectal Cancer Rep [Internet], 2017;13(5):370-401. DOI 10.1007/s11888-017-0386-1
Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017;123(13):2543-50. doi: 10.1002/cncr.30583
Menezes CCS, Ferreira DBB, Almeida FBF, Bomfim MS, Trindade LMDF. Câncer Colorretal Na População Brasileira: Taxa De Mortalidade No Período De 2005-2015. Rev. Bras Promoç Saúde [periódico na Internet]. 2016 [acesso em 2019 Maio 19];29(2):172-9 Disponível http://www.redalyc.org/articulo.oa?id=40848190004
Guinney J, Dienstmann R, Wang X, Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med [Internet], 2015;21(11):1350-6. doi:10.1038/nm.3967
Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer - a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211-9. doi:10.1001/jamaoncol.2016.4227
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
